Monika Jun, MPH

Director, CORE
Genmab

Poster(s):

• (125) Cost-effectiveness of epcoritamab vs glofitamab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) after at least 2 lines of therapy in the United States
  Wednesday, October 29, 2025